Clinical Trials Sponsored by LaSanta S A S

Total 2527 results

Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (guardian TM 7)

Congenital Bleeding Disorder | Haemophilia A

China
Novo Nordisk A/S

Completed

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes (LIRA-PRIME)

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Serbia, Turkey, Russian Federation, India, Latvia, Puerto Rico, Lebanon, Colombia
H. Lundbeck A/S

Terminated

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

Healthy | Parkinson Disease

France
Novo Nordisk A/S

Completed

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes (CAPTURE-IO)

Diabetes Mellitus, Type 2

Israel, Japan, Mexico, Argentina, Turkey, Australia, Algeria, Saudi Arabia, Brazil, China
H. Lundbeck A/S

Completed

Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700

Schizophrenia

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (guardian™ 5)

Congenital Bleeding Disorder | Haemophilia A

Italy, Sweden, Netherlands, Austria, Spain, United States, Switzerland, Germany, France, Hungary, Greece, Slovenia, Czechia, Slovakia, Poland
Novo Nordisk A/S

Completed

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

Obesity | Metabolism and Nutrition Disorder

United States, Russian Federation, Sweden, Belgium, Mexico
Novo Nordisk A/S

Completed

A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea

Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Obesity | Metabolism and Nutrition Disorder

United States, Israel, Russian Federation, United Kingdom, Canada, Belgium, Germany, Australia
Novo Nordisk A/S

Completed

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin (SCALE™ Insulin)

Obesity | Metabolism and Nutrition Disorder

United States, Israel, Italy, Mexico, Canada, Germany, Turkey
H. Lundbeck A/S

Terminated

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia (Anew)

Treatment-resistant Schizophrenia

United States, Japan, Russian Federation, Bulgaria, United Kingdom
Novo Nordisk A/S

Completed

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

Diabetes Mellitus, Type 2

United States
RSP Systems A/S

Completed

Performance Evaluation of a Novel Non-invasive Glucometer, Calibrated Against Validated Interstitial Glucose References

Diabetes Mellitus

Sweden
Novo Nordisk A/S

Completed

A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus (CAN-TREAT)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Canada
Novo Nordisk A/S

Completed

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men

Diabetes Mellitus, Type 2

Germany
H. Lundbeck A/S

Completed

Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State

Healthy

United Kingdom
Novo Nordisk A/S

Terminated

A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Obesity | Overweight

Germany
H. Lundbeck A/S

Terminated

Pharmacokinetics of Lu AF35700 in Subjects With Renal Impairment

Renal Failure

Germany
H. Lundbeck A/S

Completed

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Novo Nordisk A/S

Completed

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study (mentor™6)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

Spain, United States, Canada, Italy, United Kingdom, Hungary
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (SUSTAIN™ 4)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, United Kingdom, France, Argentina, South Africa, Germany, Slovenia, Netherlands, Romania, North Macedonia, Mexico, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes (SUSTAIN™1)

Diabetes Mellitus, Type 2 | Diabetes

United States, United Kingdom, Mexico, Russian Federation, Japan, Canada, Italy, South Africa, Romania
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects

Healthy | Diabetes

China
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Austria
Novo Nordisk A/S

Completed

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (Explorer 1)

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Austria, Sweden, Spain, Switzerland, United Kingdom, Germany, Malaysia, Denmark, South Africa, Thailand, Italy
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
H. Lundbeck A/S

Completed

Single Ascending Dose Study of Lu AF76432 in Healthy Young Men

Healthy

United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Poland, Croatia, Germany, Turkey, Slovakia, Bulgaria, Romania, Algeria, Czechia, Ukraine
H. Lundbeck A/S

Completed

Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder

Sleep Disturbances
Novo Nordisk A/S

Completed

A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Diabetes

India, Serbia, Bulgaria, Australia, Korea, Republic of, Thailand, Turkey, United Arab Emirates, Hungary
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes (SUSTAIN™)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States, Serbia, Malaysia, Thailand, Greece, Japan, Romania
Novo Nordisk A/S

Completed

A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes (DUAL™ II)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Denmark, Hungary, Slovenia, Switzerland, Bulgaria
Novo Nordisk A/S

Completed

A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan, Malaysia, Taiwan, Korea, Republic of, Hong Kong
Novo Nordisk A/S

Completed

Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

India, Denmark, Sweden, Malaysia, Poland, Turkey, Finland, Australia, Thailand, Taiwan
Novo Nordisk A/S

Completed

Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Romania, Slovakia, Israel, Saudi Arabia, India, Malaysia, Mexico, Russian Federation, Germany, Croatia, Poland, Serbia, Bulgaria, Canada, Slovenia, Sweden, Denmark, Hungary, Argentina, Austria, Finland, Lebanon, Czechia, Netherlands
RSP Systems A/S

Completed

Performance Characteristics and Safety Assessment of a Non-invasive Glucose Monitoring Device

Diabetes Mellitus

Denmark
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Inflammation | Rheumatoid Arthritis

United States, Mexico, Russian Federation, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Poland, Ukraine, Hungary
Novo Nordisk A/S

Terminated

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE) (ACTION to HOPE)

Haemophilia A, Haemophilia B, Obesity

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United States, Sweden, Serbia, Turkey, United Kingdom, Malaysia, Brazil, Former Serbia and Montenegro, Japan, South Africa
Fertin Pharma A/S

Completed

Single-Dose Bioequivalence Study Comparing Two 2 mg Nicotine Lozenges

Smoking Cessation

South Africa
H. Lundbeck A/S

Completed

Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects

Hepatic Impairment

Germany
Novo Nordisk A/S

Completed

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Hungary, Czechia
Novo Nordisk A/S

Completed

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Malaysia, Germany, Algeria, Turkey

3

Subscribe